Compare C & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | C | TMO |
|---|---|---|
| Founded | 1812 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1B | 223.0B |
| IPO Year | 2025 | 1996 |
| Metric | C | TMO |
|---|---|---|
| Price | $138.99 | $590.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 18 |
| Target Price | $134.94 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 7.1M | 2.1M |
| Earning Date | 04-14-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.88% | 0.40% |
| EPS Growth | ★ 17.68 | 7.32 |
| EPS | 6.99 | ★ 9.10 |
| Revenue | ★ $85,225,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $24.26 | $6.55 |
| Revenue Next Year | $3.63 | $5.11 |
| P/E Ratio | ★ $19.85 | $65.50 |
| Revenue Growth | 5.04 | ★ 14.47 |
| 52 Week Low | $90.68 | $435.27 |
| 52 Week High | $147.96 | $643.99 |
| Indicator | C | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 65.23 |
| Support Level | $126.15 | $557.05 |
| Resistance Level | $139.26 | $596.47 |
| Average True Range (ATR) | 2.96 | 13.61 |
| MACD | 0.78 | -0.12 |
| Stochastic Oscillator | 91.81 | 68.52 |
Citigroup is a global financial powerhouse that orchestrates the movement of $5 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm remains a leader on the global stage, servicing 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, steps have been taken to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).